SCHEMBL20689552

SCHEMBL20689552

COC(=O)c1cccn(-c2ccon2)c1=O

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TYK2 P29597 1/20 0.44
ALDH1A1 P00352 7/20 0.41
KDM4E B2RXH2 5/20 0.41
GABRA1 P14867 1/20 0.39
GABRG2 P18507 1/20 0.39
GABRB3 P28472 1/20 0.39
GABRA3 P34903 1/20 0.39
TP53 P04637 1/20 0.38
LMNA P02545 2/20 0.37
TSHR P16473 2/20 0.37
GAA P10253 4/20 0.37
BRD4 O60885 2/20 0.37
HSD17B10 Q99714 2/20 0.36
CFTR P13569 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
POLB P06746 1/20 0.36
ATM Q13315 1/20 0.36
MYC P01106 1/20 0.35
AHR P35869 1/20 0.35
NPSR1 Q6W5P4 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20689555 0.83 TYK2 (0.44) TYK2ALDH1A1KDM4ETP53TSHR
SCHEMBL20689566 0.79 TYK2 (0.48) TYK2ALDH1A1KDM4EGABRA1GABRG2
SCHEMBL4817433 0.77 TSHR (0.56) TYK2ALDH1A1KDM4EGABRA1GABRG2
SCHEMBL30367869 0.77 TSHR (0.56) TYK2ALDH1A1KDM4EGABRA1GABRG2
SCHEMBL20687710 0.74 TYK2 (0.47) TYK2ALDH1A1TP53GAA
SCHEMBL1136978 0.74 ALDH1A1 (0.60) ALDH1A1KDM4EGABRA1GABRG2GABRB3
SCHEMBL25070118 0.74 TYK2 (0.45) TYK2ALDH1A1KDM4EGABRA1GABRG2
SCHEMBL16794645 0.74 GABRG2 (0.42) TYK2ALDH1A1KDM4EGABRA1GABRG2
SCHEMBL30367362 0.74 TYK2 (0.46) TYK2ALDH1A1KDM4EGABRA1GABRG2
SCHEMBL25529013 0.74 TYK2 (0.46) TYK2ALDH1A1KDM4EGABRA1GABRG2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230056447-A1 TYK2 INHIBITORS AND USES THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2023-02-23 US disclosed
US-11046698-B2 TYK2 inhibitors and uses thereof NIMBUS LAKSHMI, INC. (US) 2021-06-29 US disclosed
US-10577373-B2 TYK2 inhibitors and uses thereof Nimbus Lakshimi, Inc. (US) 2020-03-03 US disclosed
US-10570145-B2 TYK2 inhibitors and uses thereof Nimbus Lakshimi, Inc. (US) 2020-02-25 US disclosed
US-10562907-B2 TYK2 inhibitors and uses thereof Nimbus Lakshimi, Inc. (US) 2020-02-18 US disclosed
US-20190256519-A1 TYK2 INHIBITORS AND USES THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2019-08-22 US disclosed
US-20190248797-A1 TYK2 INHIBITORS AND USES THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2019-08-15 US disclosed
US-20190241577-A1 TYK2 INHIBITORS AND USES THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2019-08-08 US disclosed
US-20190241575-A1 TYK2 INHIBITORS AND USES THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2019-08-08 US disclosed
WO-2019023468-A1 TYK2 INHIBITORS AND USES THEREOF NIMBUS LAKSHMI, INC. (US) 2019-01-31 WO disclosed
US-20190031664-A1 TYK2 INHIBITORS AND USES THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2019-01-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190248797-A1 TYK2 INHIBITORS AND USES THEREOF TYK2, JAK2, JAK1 TYK2 1/4885ALDH1A1 4827/4885KDM4E 391/4885
US-11046698-B2 TYK2 inhibitors and uses thereof TYK2, JAK2, JAK1 TYK2 1/4885ALDH1A1 4827/4885KDM4E 391/4885
US-20190256519-A1 TYK2 INHIBITORS AND USES THEREOF TYK2, JAK2, JAK1 TYK2 1/4885ALDH1A1 4827/4885KDM4E 391/4885
US-20190031664-A1 TYK2 INHIBITORS AND USES THEREOF TYK2, JAK2, JAK1 TYK2 1/4885ALDH1A1 4827/4885KDM4E 391/4885
US-20190241577-A1 TYK2 INHIBITORS AND USES THEREOF TYK2, JAK2, JAK1 TYK2 1/4885ALDH1A1 4827/4885KDM4E 391/4885
US-20190241575-A1 TYK2 INHIBITORS AND USES THEREOF TYK2, JAK2, JAK1 TYK2 1/4885ALDH1A1 4827/4885KDM4E 391/4885
US-20230056447-A1 TYK2 INHIBITORS AND USES THEREOF TYK2, JAK2, JAK1 TYK2 1/4885ALDH1A1 4827/4885KDM4E 391/4885
US-10570145-B2 TYK2 inhibitors and uses thereof TYK2, JAK2, JAK1 TYK2 1/4885ALDH1A1 4827/4885KDM4E 391/4885
US-10577373-B2 TYK2 inhibitors and uses thereof TYK2, JAK2, JAK1 TYK2 1/4885ALDH1A1 4827/4885KDM4E 391/4885
US-10562907-B2 TYK2 inhibitors and uses thereof TYK2, JAK2, JAK1 TYK2 1/4885ALDH1A1 4827/4885KDM4E 391/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.